Total Payments
$63,457
2024 Payments
$2,641
Companies
42
Transactions
594
Medicare Patients
3,360
Medicare Billing
$647,566
Payment Breakdown by Category
Other$40,282 (63.5%)
Food & Beverage$12,030 (19.0%)
Research$8,324 (13.1%)
Travel$2,783 (4.4%)
Education$38.65 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,282 | 25 | 63.5% |
| Food and Beverage | $12,030 | 532 | 19.0% |
| Unspecified | $8,324 | 24 | 13.1% |
| Travel and Lodging | $2,783 | 10 | 4.4% |
| Education | $38.65 | 3 | 0.1% |
Payments by Type
General
$55,133
570 transactions
Research
$8,324
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $43,707 | 139 | $0 (2024) |
| Eli Lilly and Company | $4,050 | 1 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $1,929 | 93 | $0 (2024) |
| AstraZeneca UK Limited | $1,711 | 10 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $1,699 | 25 | $0 (2024) |
| SANOFI US SERVICES INC. | $1,655 | 9 | $0 (2023) |
| Octapharma USA, Inc. | $1,356 | 22 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $1,178 | 8 | $0 (2024) |
| Pharming Healthcare, Inc. | $1,047 | 13 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $840.26 | 35 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,641 | 82 | Regeneron Pharmaceuticals, Inc. ($1,178) |
| 2023 | $18,930 | 88 | GlaxoSmithKline, LLC. ($14,847) |
| 2022 | $10,464 | 76 | GlaxoSmithKline, LLC. ($7,918) |
| 2021 | $16,056 | 71 | GlaxoSmithKline, LLC. ($14,807) |
| 2020 | $9,643 | 76 | Eli Lilly and Company ($4,050) |
| 2019 | $1,835 | 76 | Octapharma USA, Inc. ($531.99) |
| 2018 | $2,537 | 59 | GlaxoSmithKline, LLC. ($1,599) |
| 2017 | $1,352 | 66 | AstraZeneca UK Limited ($458.50) |
All Payment Transactions
594 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: Inflammation | ||||||
| 12/11/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/03/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $35.82 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $7.11 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | Octapharma USA, Inc. | CUTAQUIG (Biological) | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $6.92 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: Respiratory | ||||||
| 10/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/24/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: Immunology | ||||||
| 10/21/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $23.99 | General |
| Category: Oncology / Rare Diseases | ||||||
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: Respiratory | ||||||
| 10/09/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.31 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/09/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: RESPIRATORY | ||||||
| 10/08/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $7.08 | General |
| Category: IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $198.23 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $123.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $60.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $47.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $24.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $24.00 | Research |
| Study: AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/24/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: RESPIRATORY | ||||||
| 09/16/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $2.92 | General |
| Category: IMMUNOLOGY | ||||||
| 09/11/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $24.59 | General |
| Category: Immunology | ||||||
| 09/10/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $125.03 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES | Eli Lilly and Company | $4,050 | 1 |
| A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | SANOFI US SERVICES INC. | $1,655 | 9 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTER, STRATIFIED ST | GlaxoSmithKline, LLC. | $1,441 | 6 |
| AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma | Regeneron Pharmaceuticals, Inc. | $1,178 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 961 | 16,734 | $464,888 | $189,196 |
| 2022 | 11 | 927 | 16,431 | $464,175 | $192,267 |
| 2021 | 11 | 821 | 12,475 | $373,498 | $162,474 |
| 2020 | 11 | 651 | 9,267 | $276,057 | $103,629 |
Total Patients
3,360
Total Services
54,907
Medicare Billing
$647,566
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 114 | 5,590 | $139,750 | $70,481 | 50.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 243 | 405 | $52,650 | $27,462 | 52.2% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 131 | 2,285 | $82,260 | $21,068 | 25.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 133 | 207 | $39,330 | $20,714 | 52.7% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 68 | 5,571 | $69,638 | $18,065 | 25.9% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 54 | 1,137 | $17,055 | $7,780 | 45.6% |
| 95144 | Professional service for preparation and provision of single-dose vial of allergen | Office | 2023 | 11 | 510 | $12,750 | $7,311 | 57.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $11,400 | $4,583 | 40.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 53 | 53 | $10,600 | $4,081 | 38.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 48 | $5,280 | $2,939 | 55.7% |
| 95044 | Test for allergy using skin patch | Office | 2023 | 16 | 576 | $9,216 | $2,279 | 24.7% |
| 95115 | Professional service for single injection of allergen | Office | 2023 | 20 | 164 | $4,264 | $1,095 | 25.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 33 | 33 | $7,920 | $972.16 | 12.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 29 | $1,015 | $299.08 | 29.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 19 | 88 | $1,760 | $68.05 | 3.9% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 120 | 6,730 | $168,250 | $85,979 | 51.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 171 | 275 | $52,250 | $27,053 | 51.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 205 | 298 | $38,740 | $20,094 | 51.9% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 143 | 2,207 | $79,452 | $19,859 | 25.0% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 65 | 5,110 | $63,875 | $16,612 | 26.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 91 | 91 | $24,200 | $11,577 | 47.8% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2022 | 48 | 1,000 | $15,000 | $6,925 | 46.2% |
| 95044 | Test for allergy using skin patch | Office | 2022 | 13 | 469 | $7,504 | $1,866 | 24.9% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 41 | 41 | $9,840 | $1,242 | 12.6% |
| 95115 | Professional service for single injection of allergen | Office | 2022 | 16 | 144 | $3,744 | $1,006 | 26.9% |
About Dr. Eric Boren, MD
Dr. Eric Boren, MD is a Allergy & Immunology healthcare provider based in Bakersfield, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720067598.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Boren, MD has received a total of $63,457 in payments from pharmaceutical and medical device companies, with $2,641 received in 2024. These payments were reported across 594 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($40,282).
As a Medicare-enrolled provider, Boren has provided services to 3,360 Medicare beneficiaries, totaling 54,907 services with total Medicare billing of $647,566. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Other Specialties Internal Medicine
- Location Bakersfield, CA
- Active Since 01/11/2006
- Last Updated 07/31/2008
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1720067598
Products in Payments
- TRELEGY ELLIPTA (Drug) $23,826
- DUPIXENT (Biological) $3,763
- CUTAQUIG (Biological) $1,391
- RUCONEST (Biological) $1,047
- NUCALA (Biological) $867.34
- CUVITRU (Biological) $646.33
- BEVESPI AEROSPHERE (Drug) $492.87
- TAKHZYRO (Biological) $359.49
- Haegarda (Biological) $338.20
- ORLADEYO (Drug) $299.78
- SYMBICORT (Drug) $246.86
- TEZSPIRE (Biological) $239.37
- XOLAIR (Biological) $231.73
- EUCRISA (Drug) $226.73
- AIRSUPRA (Drug) $186.78
- AYVAKIT (Drug) $174.40
- BREZTRI (Drug) $154.05
- Hizentra (Biological) $153.65
- BREO (Drug) $147.28
- PANZYGA (Biological) $122.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.